12-1839-41

antibody from Invitrogen Antibodies

Targeting: CXCR3 CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

12-1839-41

Provider

Invitrogen Antibodies

Product name

CD183 (CXCR3) Monoclonal Antibody (CEW33D), PE, eBioscience™

Antibody type

Monoclonal

Antigen

Other

Description

Description: The CEW33D monoclonal antibody reacts with human CD183. CD183, also known as CXCR3, is a G protein-coupled chemokine receptor that interacts with ligands CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC). Strongly associated with type 1 immunity, CD183 is induced in naive T cells upon activation and remains upregulated in T helper type (Th)1 cells, CD8 effector cells, NK cells and NKT cells. CD183-ligand interactions mediate infiltration of inflamed tissues in normal type 1 immune responses as well as in many inflammatory and autoimmune diseases. CD183 is also expressed on some B cells and plasmacytoid DC.

Conjugate

Yellow dye

Antibody clone number

CEW33D

Concentration

5 µL/Test

References

Submitted references

Application of the chemokine-chemokine receptor axis increases the tumor-targeted migration ability of cytokine-induced killer cells in patients with colorectal cancer.

Zou Y, Liang J, Li D, Fang J, Wang L, Wang J, Zhang J, Guo Q, Yan X, Tang H
Oncology letters 2020 Jul;20(1):123-134

---

Chloroquine inhibits human CD4(+) T-cell activation by AP-1 signaling modulation.

Schmidt RL, Jutz S, Goldhahn K, Witzeneder N, Gerner MC, Trapin D, Greiner G, Hoermann G, Steiner G, Pickl WF, Burgmann H, Steinberger P, Ratzinger F, Schmetterer KG
Scientific reports 2017 Feb 7;7:42191

---

Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3.

Hoerning A, Koss K, Datta D, Boneschansker L, Jones CN, Wong IY, Irimia D, Calzadilla K, Benitez F, Hoyer PF, Harmon WE, Briscoe DM
European journal of immunology 2011 Aug;41(8):2291-302

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Staining of normal human peripheral blood cells with Anti-Human CD3 FITC (Product # 11-0038-42) and Mouse IgG1 K Isotype Control PE (Product # 12-4714-81) (left) or Anti-Human CD183 (CXCR3) PE (right). Cells in the lymphocyte gate were used for analysis.

Conjugate

Yellow dye

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

3 Co-expression of CXCR3 with FOXP3, CTLA-4 and CD39 on CD4 + T cells. (A and B) Representative flow cytometry plots illustrating co-expression of CXCR3 and CD25 on (A) the CD4 + FOXP3 + T-cell subset and (B) the CD4 + CTLA-4 + subset. Staining with isotype control antibodies is shown on the right of each dot plot. (C) Median, 25th and 75th percentile and range of CXCR3 expression on CD4 + FOXP3 + or CD4 + CTLA-4 + subsets. (D and E) Representative flow cytometry plots of CXCR3 expression on (D) double positive FOXP3 + CTLA-4 + cells and (E) FOXP3 + CD39 + cells after gating on CD4 + cells. The box plot on the right of each panel illustrates median, 25th and 75th percentile and range of expression in multiple experiments. (F) Fold difference (mean+SEM) in mRNA expression for Tbet in sorted populations of CD4 + CD25 hi CXCR3 pos cells (white bars) or CD4 + CD25 hi CXCR3 neg Tregs (black bars). Expression was evaluated in unactivated Tregs (left panel) or in Tregs following 6 h activation with anti-CD3/anti-CD28 (right panel). Representative of n =3 experiments with similar results.

Conjugate

Yellow dye